My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    Thromb Haemost. 1998 Oct;80(4):607-9.

    The risk of mortality and the factor V Leiden mutation in a population-based cohort.

    Heijmans BT, Westendorp RG, Knook DL, Kluft C, Slagboom PE.

    Gaubius Laboratory, TNO Prevention and Health, Leiden, The Netherlands.

    The factor V Leiden mutation (conferring resistance to activated protein C) has been implicated in the risk of arterial thrombosis and is a well-established risk factor for venous thrombosis especially in the elderly. We studied whether the disease association of the factor V mutation is reflected in an increased all-cause and cause-specific mortality. First, the prevalence of the factor V Leiden mutation was determined in a population-based study among subjects aged 85 years and over (4.7%, n = 660) and was found to correspond to the prevalence in young subjects aged 18 to 40 years (5.0%, n = 321). Secondly, we studied the association of factor V Leiden with the risk of all-cause mortality and specific causes of death in the elderly cohort during a 10-year follow-up period. Neither the all-cause mortality risk (RR 1.0; 95% CI, 0.7-1.5), nor the risk of death due to cardiovascular disease (RR 0.9; 95% CI, 0.5-1.7) were increased in elderly subjects heterozygous for factor V Leiden. Our study thus indicates that heterozygosity for factor V Leiden does not affect population mortality.

    PMID: 9798979 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read
    Write to the Help Desk